Tumors of the digestive tract About themeOur mission is to arrive at an optimal classification of patients to improve surveillance, diagnosis, treatment, and outcome for patients with cancer of the digestive tract.
In our theme, we are committed to improving outcome for patients with cancer of the digestive tract. To this end, we aim our research at selecting patients for their personalized trajectory. We use basic, translational, and clinical research to provide the evidence for this trajectory. This involves surveillance and early detection, optimal diagnosis including molecular analyses and innovative imaging, and innovation in treatment, ranging from improved surgical techniques to immunotherapy.
- We will identify new genes responsible for hereditary colorectal cancer syndromes.
- We will develop strategies for improving detection of hereditary forms of pancreatic cancer.
- We aim to prevent cancer in high-risk patients using vaccination and lifestyle interventions.
- We will develop new molecular diagnostic tools to predict tumor response to therapy.
- We will identify relevant biomarkers for the development of metastatic disease and implement these factors in daily practice.
- We will develop surgical techniques to optimize patient care.
Lines of research
Evidence-based pathologyDetection, validation, and implementation of new and classic biomarkers in the different patient cohorts have direct effect on treatment of patients. This topic together with the previous research line come together in the Laboratory for tumor genetics, where patient care is combined with biomarker research.
News & agendas
- Lynch syndrome from basic research to implementation in daily clinical practice
- Microbiome: from association studies towards clinically relevant tools
- Evidence-based pathology: guiding personalized treatment
- Imaging: getting ready for the next challenges
- Surgery: improved outcomes due to improved care
- Epidemiology: Study of variation to improve future care
Centers of clinical expertise
Information might be only available in Dutch.